102 Participants Needed

SBRT vs Conventional Radiation + Chemotherapy for Pancreatic Cancer

MC
Overseen ByMedical College of Wisconsin Cancer Center Clinical Trials Office
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Medical College of Wisconsin
Must be taking: Chemotherapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications for this trial?

The trial protocol does not specify if you need to stop taking your current medications, but it does mention that patients taking nonprotocol-specified chemotherapy agents or immune modulating agents for other conditions cannot participate. It's best to discuss your current medications with the trial's principal investigator.

What data supports the effectiveness of the treatment Preoperative Fractionated Radiation Therapy and Chemotherapy, Stereotactic Body Radiation Therapy, Stereotactic Ablative Radiotherapy (SABR), CyberKnife for pancreatic cancer?

Research shows that stereotactic ablative radiation therapy (SABR) and stereotactic body radiation therapy (SBRT) using CyberKnife can be effective for treating locally advanced and metastatic pancreatic cancer, especially after initial chemotherapy. These treatments are known for their precision and shorter treatment times, which can be beneficial for patients.12345

Is SBRT using CyberKnife safe for pancreatic cancer patients?

Studies have evaluated the safety of Stereotactic Body Radiation Therapy (SBRT) using CyberKnife for pancreatic cancer, showing it is generally safe for patients, including those with advanced or recurrent conditions. Safety has also been assessed in other cancers, like liver cancer, indicating it is a well-tolerated treatment option.24567

How is the SBRT treatment different from other treatments for pancreatic cancer?

SBRT (Stereotactic Body Radiation Therapy) is unique because it delivers high doses of radiation in a shorter time compared to conventional radiation, which can minimize disruption to chemotherapy schedules and potentially improve surgical outcomes and survival rates for pancreatic cancer patients.89101112

What is the purpose of this trial?

Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.

Research Team

WH

William Hall, MD

Principal Investigator

Medical College of Wisconsin

Eligibility Criteria

Adults over 18 with a specific type of pancreatic cancer (type A adenocarcinoma) that is resectable, borderline resectable, or locally advanced. They should have had two months of chemotherapy without disease spread and be able to swallow pills. Pregnant women and those not using contraception are excluded.

Inclusion Criteria

Heme Onc (Chem 24) and cancer antigen (CA) 19-9/carcinoembryonic antigen (CEA) within 30 days prior to treatment, as follows:
Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
Patient must provide study-specific informed consent prior to study entry.
See 19 more

Exclusion Criteria

Participation in another interventional clinical treatment trial while on study (observational trials are permitted).
I don't have any major health issues that would prevent me from having major pancreatic surgery.
Women who are lactating at the time of registration and who plan to be lactating through three months after study therapy is completed.
See 16 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction Chemotherapy

Participants receive a minimum of one cycle of induction chemotherapy before randomization

4-6 weeks

Treatment

Participants are randomized to receive either Stereotactic Body Radiation Therapy (SBRT) or conventional concurrent chemotherapy and radiation therapy

5-6 weeks

Surgical Resection

Subjects undergo surgical resection within three to eight weeks following treatment

3-8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

8 weeks

Treatment Details

Interventions

  • Preoperative Fractionated Radiation Therapy and Chemotherapy
  • Stereotactic Body Radiation Therapy
Trial Overview The trial compares two treatments for pancreatic cancer: Arm A receives Stereotactic Body Radiation Therapy (SBRT), while Arm B gets conventional chemotherapy alongside radiation therapy. Patients are randomly assigned to one of these groups.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Stereotactic Body Radiation TherapyExperimental Treatment1 Intervention
Patients undergo Stereotactic Body Radiation Therapy (25 to 35 Gy over five fractions)
Group II: Preoperative Fractionated Radiation Therapy and ChemotherapyExperimental Treatment1 Intervention
Concurrent chemotherapy with radiation treatment (50.4 Gy over 28 fractions).

Find a Clinic Near You

Who Is Running the Clinical Trial?

Medical College of Wisconsin

Lead Sponsor

Trials
645
Recruited
1,180,000+

Findings from Research

In a study of 74 patients with locally advanced pancreatic cancer (LAPC) treated with chemotherapy followed by stereotactic ablative radiation therapy (SABR), the median overall survival was 19.6 months from diagnosis and 12.1 months from the start of SABR, indicating promising efficacy of this treatment approach.
SABR was found to be well-tolerated, with only a 2.7% rate of severe fatigue and late gastrointestinal toxicity, and better outcomes were associated with patients who had a Karnofsky Performance Status (KPS) score of ≥90, were younger than 70 years, and had no pain prior to treatment.
Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort.Doppenberg, D., Lagerwaard, FJ., van Dieren, S., et al.[2023]
Stereotactic body radiotherapy using the CyberKnife system showed a median survival of 9 months for patients with locally advanced and metastatic pancreatic cancer, with 37% of patients surviving for at least one year.
The treatment provided significant relief from abdominal pain within two weeks for 13 out of 20 patients, and it had a low toxicity profile, with only 20% experiencing mild nausea and no severe side effects reported.
Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer.Su, TS., Liang, P., Lu, HZ., et al.[2018]
Stereotactic ablative radiation therapy (SABR) for metastatic pancreatic cancer showed significant effectiveness in reducing abdominal pain and decreasing the need for opioids, with a 46% relative reduction in opioid use after treatment.
In a study of 27 patients, SABR was found to be safe, with only 7% experiencing severe toxicity, and it resulted in a median overall survival of 7 months, indicating its potential as a palliative treatment option.
The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma.Koong, AJ., Toesca, DAS., Baclay, JRM., et al.[2023]

References

Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort. [2023]
Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. [2018]
The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. [2023]
Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. [2020]
Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. [2023]
Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study. [2022]
Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization. [2022]
Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. [2023]
Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. [2022]
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security